JP2019532953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532953A5 JP2019532953A5 JP2019517396A JP2019517396A JP2019532953A5 JP 2019532953 A5 JP2019532953 A5 JP 2019532953A5 JP 2019517396 A JP2019517396 A JP 2019517396A JP 2019517396 A JP2019517396 A JP 2019517396A JP 2019532953 A5 JP2019532953 A5 JP 2019532953A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- immune effector
- amino acid
- cancer
- effector cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/101213 | 2016-09-30 | ||
| CN2016101213 | 2016-09-30 | ||
| PCT/CN2017/104422 WO2018059549A1 (en) | 2016-09-30 | 2017-09-29 | Immune effector cell therapies with enhanced efficacy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532953A JP2019532953A (ja) | 2019-11-14 |
| JP2019532953A5 true JP2019532953A5 (https=) | 2021-08-12 |
Family
ID=61763296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517396A Pending JP2019532953A (ja) | 2016-09-30 | 2017-09-29 | 増強された有効性を有する免疫エフェクター細胞治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190298715A1 (https=) |
| EP (1) | EP3523290A4 (https=) |
| JP (1) | JP2019532953A (https=) |
| CN (1) | CN110582488A (https=) |
| WO (1) | WO2018059549A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| JP6647868B2 (ja) | 2013-02-20 | 2020-02-14 | ノバルティス アーゲー | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| WO2015112626A1 (en) | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| TWI719942B (zh) | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | 使用ｃｄ３３嵌合抗原受體治療癌症 |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| MX2017002205A (es) | 2014-08-19 | 2017-08-21 | Novartis Ag | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. |
| KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| JP6961490B2 (ja) | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CA2992551A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| WO2017093969A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| RU2018127657A (ru) * | 2015-12-30 | 2020-01-31 | Новартис Аг | Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| BR112019006781A2 (pt) | 2016-10-07 | 2019-07-30 | Novartis Ag | receptores de antígeno quiméricos para o tratamento de câncer |
| ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
| WO2018175636A2 (en) | 2017-03-22 | 2018-09-27 | Novartis Ag | Compositions and methods for immunooncology |
| UY37774A (es) * | 2017-06-19 | 2019-01-31 | Novartis Ag | Compuestos 5-cianoindol sustituidos y usos de los mismos |
| AU2018351050B2 (en) | 2017-10-18 | 2025-09-18 | Novartis Ag | Compositions and methods for selective protein degradation |
| US12539308B2 (en) | 2018-01-08 | 2026-02-03 | The Trustees Of The University Of Pennsylvania | Immune-enhancing RNAs for combination with chimeric antigen receptor therapy |
| CN112533617A (zh) * | 2018-04-25 | 2021-03-19 | 卫理公会医院体系公司 | 癌症新抗原和其在癌症疫苗和基于tcr的癌症免疫疗法中的效用 |
| TWI890660B (zh) | 2018-06-13 | 2025-07-21 | 瑞士商諾華公司 | Bcma 嵌合抗原受體及其用途 |
| EP4065157A1 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| IL293215A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors that bind bcma and cd19 and their uses |
| CA3170023A1 (en) * | 2020-02-27 | 2021-09-02 | Nanjing Legend Biotech Co., Ltd. | Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof |
| CN115803092A (zh) * | 2020-04-24 | 2023-03-14 | 乔治亚州立大学研究基金公司 | 用于治疗癌症的缺乏SIRPα的巨噬细胞 |
| CA3158133A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CA3187944A1 (en) | 2020-06-22 | 2021-12-30 | Ngm Biopharmaceuticals, Inc. | Lair-1-binding agents and methods of use thereof |
| CA3195121A1 (en) * | 2020-10-09 | 2022-04-14 | Robert A. Volkmann | Heteroaryl amide inhibitors of cd38 |
| CN114426952A (zh) * | 2020-10-29 | 2022-05-03 | 中国科学技术大学 | 用于白血病的car t细胞疗法的t细胞增效剂及获得增效t细胞的方法 |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| TW202307210A (zh) | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 |
| CN113462723B (zh) * | 2021-07-05 | 2023-07-11 | 北京中医药大学 | 表达CAR和shRNA的逆转录病毒载体及其应用 |
| JP2025517410A (ja) * | 2022-05-20 | 2025-06-05 | イマーゴ バイオサイエンシーズ インコーポレイテッド | Ｃａｒ－ｔ細胞の治療効果の増強方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050113564A1 (en) * | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| DE102008052943A1 (de) * | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
| EP2712316A1 (en) * | 2011-02-08 | 2014-04-02 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| US9289415B2 (en) * | 2011-09-01 | 2016-03-22 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| US10316289B2 (en) * | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| WO2014165707A2 (en) * | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| CA2916533C (en) * | 2013-06-25 | 2022-12-20 | University Of Canberra | Methods and compositions for modulating cancer stem cells |
| EP3027755B1 (en) * | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| US20150250824A1 (en) * | 2014-03-07 | 2015-09-10 | The Research Foundation For The State University Of New York | Methods and compositions for expansion of stem cells and other cells |
| CA2941716A1 (en) * | 2014-03-07 | 2015-09-11 | The Johns Hopkins University | Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs) |
| KR102400920B1 (ko) * | 2014-05-01 | 2022-05-20 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
| WO2015181380A1 (en) * | 2014-05-30 | 2015-12-03 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Cyclopropylamine compounds as histone demethylase inhibitors |
| BR112017001183A2 (pt) * | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| CA2958704A1 (en) * | 2014-08-25 | 2016-03-03 | University Of Canberra | Compositions for modulating cancer stem cells and uses therefor |
| RU2018127657A (ru) * | 2015-12-30 | 2020-01-31 | Новартис Аг | Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью |
| CN110267945A (zh) * | 2016-03-01 | 2019-09-20 | 诺华股份有限公司 | 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途 |
-
2017
- 2017-09-29 JP JP2019517396A patent/JP2019532953A/ja active Pending
- 2017-09-29 WO PCT/CN2017/104422 patent/WO2018059549A1/en not_active Ceased
- 2017-09-29 US US16/338,085 patent/US20190298715A1/en not_active Abandoned
- 2017-09-29 CN CN201780073475.5A patent/CN110582488A/zh active Pending
- 2017-09-29 EP EP17854999.4A patent/EP3523290A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532953A5 (https=) | ||
| JP2019500394A5 (https=) | ||
| RU2018127657A (ru) | Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью | |
| JP2018527008A5 (https=) | ||
| JP2020513828A5 (https=) | ||
| RU2019133286A (ru) | Биомаркеры и средства терапии на основе т-клеток с car с повышенной эффективностью | |
| US11564945B2 (en) | Chimeric antigen receptor and use thereof | |
| JP2023529211A5 (https=) | ||
| JP2017513818A5 (https=) | ||
| JP2021534783A5 (https=) | ||
| JP2023516008A5 (https=) | ||
| JP2020506700A5 (https=) | ||
| JP2017530694A5 (https=) | ||
| JP2024045111A (ja) | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 | |
| JP2019525956A5 (https=) | ||
| JP2020500530A5 (https=) | ||
| WO2018059549A1 (en) | Immune effector cell therapies with enhanced efficacy | |
| JP2017522879A5 (https=) | ||
| JP2016514462A5 (https=) | ||
| JP2017527271A5 (https=) | ||
| JP2022512882A5 (https=) | ||
| US12178786B2 (en) | Combination of cellular immunotherapy | |
| JP2022524906A (ja) | 細胞免疫療法の組み合わせ | |
| JP2022517301A (ja) | 腫瘍併用免疫療法 | |
| CN112040957A (zh) | 靶向表达cd99的癌症的组合物和方法 |